Related Experiment Video

Updated: Jun 5, 2026

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

TAK1 regulates SCF expression to modulate PKBα activity that protects keratinocytes from ROS-induced apoptosis

C R I Lam1, M J Tan, S H Tan

  • 1School of Biological Sciences, Nanyang Technological University, Singapore.

Cell Death and Differentiation
|January 15, 2011
PubMed

Insights

Transforming growth factor-activated kinase 1 (TAK1) regulates stem cell factor (SCF) to protect skin cells from reactive oxygen species (ROS) damage during wound healing, revealing a novel anti-apoptotic mechanism.

Area of Science:

  • Skin Biology
  • Redox Biology
  • Inflammation Signaling

Background:

  • Dysregulated reactive oxygen species (ROS) contribute to pathologies like cancer and diabetes.
  • Controlled ROS production is crucial for wound repair, but regulatory mechanisms are unclear.
  • Transforming growth factor-activated kinase 1 (TAK1) is a key inflammatory mediator.

Purpose of the Study:

  • To elucidate the role of TAK1 in regulating ROS production and cell survival in keratinocytes.
  • To identify the signaling pathways involved in TAK1-mediated protection against ROS-induced apoptosis.
  • To explore the function of stem cell factor (SCF) in skin redox homeostasis.

Main Methods:

  • Investigated TAK1 expression during wound healing.
  • Utilized keratinocyte cultures, organotypic skin co-cultures, and FACS analysis for ROS detection.
  • Employed gene expression analysis (growth factor array) and pharmacological inhibition of signaling pathways.
  • Assessed apoptosis induction via anoikis and TNF-α treatment.

Main Results:

  • TAK1 deficiency in keratinocytes increased apoptosis and ROS levels.
  • TAK1 directly regulates stem cell factor (SCF) expression.
  • The SCF/c-Kit/Protein Kinase B alpha (PKBα) pathway mediates cell-autonomous protection against ROS.
  • Restoring TAK1 or SCF levels rescued TAK1-deficient keratinocytes from apoptosis and excessive ROS.

Conclusions:

  • TAK1 plays a critical role in controlling ROS levels and preventing keratinocyte apoptosis during wound repair.
  • TAK1 regulates keratinocyte survival through the SCF/c-Kit/PKBα signaling axis.
  • Stem cell factor (SCF) exhibits a novel anti-apoptotic function in keratinocytes, linking inflammation and redox regulation.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...